Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 drug interaction study with midazolam in healthy volunteers
NCT06610890Phase 1Completed
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mufemilast in psoriasis, sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve and 1 more. Started Dec 2024; status: completed.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06610890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610890.